Repeated Oral THC Changed Plasma Profiles Beyond the First-Dose Peak
A first-dose plasma peak does not describe the full exposure pattern during repeated oral THC administration. A six-person inpatient study found changing THC and metabolite profiles during an escalating, around-the-clock regimen, with important analytical limits on conjugated measurements.
A high-dose regimen in established users
Schwilke and colleagues studied daily cannabis users receiving 20 mg oral dronabinol capsules at progressively shorter intervals. Daily totals ranged from 40 to 120 mg during the protocol. Participants were monitored on a secure research unit, and plasma was separated from collected blood.
This was a small human pharmacokinetic experiment in cannabis-experienced adults. It was not a typical single edible exposure, a trial in cannabis-naive patients, or a study establishing driving-performance thresholds.
The first peak and later maxima answered different questions
After the first dose, mean free THC peaked at 16.5 ng/mL at approximately 2.8 hours. During continued dosing, the reported mean maximum free THC concentration was 47.7 ng/mL. The metabolite maxima occurred on different schedules, illustrating why one analyte’s first-dose timing cannot describe the whole regimen.
Predose plasma already contained cannabinoids from cannabis used before admission. Baseline subtraction and exposure history therefore mattered: a positive first sample was not evidence that the experimental capsule had already been taken.
Conjugate recovery limited the word ‘total’
The investigators tested enzymatic hydrolysis in different matrices and found incomplete, matrix-dependent recovery from plasma. Some alternative preparation approaches produced poor chromatography. They explicitly cautioned that available measurements could underestimate conjugated cannabinoids and did not establish a complete total-cannabinoid inventory.
That methodological limitation does not erase the free-analyte time courses. It restricts claims about total exposure and comparisons with methods that define or recover conjugates differently. The small sample and intensive dosing schedule also limit generalization.
For a real case, distinguish free from hydrolyzed measurements, plasma from whole blood, and repeated dosing from a single dose. A concentration accumulated under this protocol cannot be translated into a universal impairment level. Our explanation of THC concentration and impairment addresses that further inference.
Primary research
Eugene W. Schwilke and colleagues. Clinical chemistry (2009). Δ9-Tetrahydrocannabinol (THC), 11-Hydroxy-THC, and 11-Nor-9-carboxy-THC Plasma Pharmacokinetics during and after Continuous High-Dose Oral THC.
